Clinical Trial Update: Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating three regimens for older patients with previously untreated chronic lymphocytic leukemia: Rituximab plus Bendamustine, Rituximab plus I…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Bendamustine Hydrochloride (bendamustine)
• Ibrutinib (ibrutinib)
• Rituximab (rituximab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2019-12-30